AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, a proprietary processed nerve allograft for bridging severed nerves without the comorbidities associated with a nerve autograft surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. It also offe...
13631 Progress Boulevard
Alachua, FL 32615
AxoGen, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 04:30 PM
Mar 16 15
AxoGen, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 04:30 PM. Venue: MGM Grand Hotel, Las Vegas, Nevada, United States.
AxoGen, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for 2015
Mar 5 15
AxoGen, Inc. announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, revenues totaled $4.79 million, a 61% increase compared to $2.98 million in the prior year fourth quarter. Net loss was $6.5 million or $0.35 per share compared to net loss of $4.1 million or $0.24 per share for the fourth quarter of 2013.
For the year, revenues were $16,817,403 against $10,947,361 a year ago. Loss from operations was $9,800,790 against $9,592,205 a year ago. Net Loss available to common shareholders was $17,710,476 against $14,556,885 a year ago. Basic and diluted loss per share was $0.99 against $1.08 a year ago. Net cash used for operating activities was $10,451,059 against $10,444,758 a year ago. Purchase of property and equipment was $542,045 against $178,776 a year ago. Acquisition of intangible assets was $52,002 against $65,189 a year ago.
Based on the market's increasing awareness of the company's product portfolio, continued expansion of its sales footprint and current sales pipeline, the company currently anticipates 2015 full year revenue to exceed $24 million and annual gross margin in the mid to high 70% range.
AxoGen, Inc. to Report Q4, 2014 Results on Mar 05, 2015
Feb 26 15
AxoGen, Inc. announced that they will report Q4, 2014 results After-Market on Mar 05, 2015